Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

References

• Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. Accelerating next-generation vaccine development for global disease prevention. Science. 2013;340:1232910. doi:10.1126/science.1232910. PMID:23723240
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Lythgoe MP. Application of “systems vaccinology” to evaluate inflammation and reactogenicity of adjuvanted preventative vaccines. J Immunol Res. 2015;2015:909406. doi:10.1155/2015/909406. PMID:26380327
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8:360-76. doi:10.1002/cmdc.201200487. PMID:23316023
   PubMed Web of Science ®Google Scholar
• Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015;3:320-43. doi:10.3390/vaccines3020320. PMID:26343190
   PubMed Web of Science ®Google Scholar
• Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011;239:149-66. doi:10.1111/j.1600-065X.2010.00972.x. PMID:21198670
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597-608. doi:10.1038/nm.3409. PMID:24309663
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Fox CB. New generation adjuvants–from empiricism to rational design. Vaccine. 2015;33(Suppl 2):B14-20. doi:10.1016/j.vaccine.2015.01.088. PMID:26022561
   PubMed Web of Science ®Google Scholar
• Wen Y, Shi Y. Alum: an old dog with new tricks. Emerg Microbes Infect. 2016;5:e25. doi:10.1038/emi.2016.40. PMID:27004761
   PubMed Web of Science ®Google Scholar
• Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol. 2008;181:17-21. doi:10.4049/jimmunol.181.1.17. PMID:18566365
   PubMed Web of Science ®Google Scholar
• al-Shakhshir RH, Regnier FE, White JL, Hem SL. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine. 1995;13:41-4. doi:10.1016/0264-410X(95)80009-3. PMID:7762276
   PubMed Web of Science ®Google Scholar
• Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012;26:1272-9. doi:10.1096/fj.11-184556. PMID:22106367
   PubMed Web of Science ®Google Scholar
• Brewer KD, Lake K, Pelot N, Stanford MM, DeBay DR, Penwell A, Weir GM, Karkada M, Mansour M, Bowen CV. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine. 2014;32:6956-62. doi:10.1016/j.vaccine.2014.10.058. PMID:25444822
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med. 2012;10:156. doi:10.1186/1479-5876-10-156. PMID:22862954
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015;4:e1026529. doi:10.1080/2162402X.2015.1026529. PMID:26405584
   PubMed Web of Science ®Google Scholar
• MacDonald LD, Fuentes-Ortega A, Sammatur L, Mansour M. Efficacy of a single dose hepatitis B depot vaccine. Vaccine. 2010;28:7143-5. doi:10.1016/j.vaccine.2010.08.084. PMID:20832491
   PubMed Web of Science ®Google Scholar
• Committee IoMUVS. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington,(DC: National Academies Press (US), 1994.
   Google Scholar
• Siegrist CA. Mechanisms underlying adverse reactions to vaccines. J Comp Pathol. 2007;137(Suppl 1):S46-50. doi:10.1016/j.jcpa.2007.04.012. PMID:17559869
   PubMed Web of Science ®Google Scholar
• Schepens B, Sedeyn K, Vande Ginste L, De Baets S, Schotsaert M, Roose K, Houspie L, Van Ranst M, Gilbert B, van Rooijen N, et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014;6:1436-54. doi:10.15252/emmm.201404005. PMID:25298406
   PubMed Web of Science ®Google Scholar
• Leach MW, Rottman JB, Hock MB, Finco D, Rojko JL, Beyer JC. Immunogenicity/hypersensitivity of biologics. Toxicol Pathol. 2014;42:293-300. doi:10.1177/0192623313510987. PMID:24240973
   PubMed Web of Science ®Google Scholar
• Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011;108:12413-8. doi:10.1073/pnas.1105695108. PMID:21746933
   PubMed Web of Science ®Google Scholar
• Kurella S, Manocha M, Sabhnani L, Thomas B, Rao DN. New age adjuvants and delivery systems for subunit vaccines. Indian J Clin Biochem. 2000;15:83-100. doi:10.1007/BF02867548. PMID:23105272
   PubMedGoogle Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-61. doi:10.1096/fj.07-9574LSF. PMID:17942826
   PubMed Web of Science ®Google Scholar
• Krishnan L, Twine S, Gerdts V, Barreto L, Richards JC. Canadian Adjuvant Initiative Workshop, March 26–27, 2013–Ottawa, Canada. Hum Vaccin Immunother. 2014;10:519-26. doi:10.4161/hv.26972. PMID:24192752
   PubMed Web of Science ®Google Scholar
• Brito LA, O'Hagan DT. Designing and building the next generation of improved vaccine adjuvants. J Control Release. 2014;190:563-79. doi:10.1016/j.jconrel.2014.06.027. PMID:24998942
   PubMed Web of Science ®Google Scholar
• Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10:539-50. doi:10.1586/erv.11.21. PMID:21506650
   PubMed Web of Science ®Google Scholar
• Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: Progress and Challenges. Vaccines (Basel). 2014;2:515-36. doi:10.3390/vaccines2030515. PMID:26344743
   PubMedGoogle Scholar
• Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine. 2005;23:3210-22. doi:10.1016/j.vaccine.2004.11.072. PMID:15837222
   PubMed Web of Science ®Google Scholar
• Forster R. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods. 2012;66:1-7. doi:10.1016/j.vascn.2012.04.003. PMID:22561062
   PubMed Web of Science ®Google Scholar
• Quakkelaar ED, Fransen MF, van Maren WW, Vaneman J, Loof NM, van Heiningen SH, Verbeek JS, Ossendorp F, Melief CJ. IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation. J Immunol. 2014;192:5813-20. doi:10.4049/jimmunol.1302337. PMID:24813207
   PubMed Web of Science ®Google Scholar
• Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother. 2010;33:250-61. doi:10.1097/CJI.0b013e3181c1f1e9. PMID:20445345
   PubMed Web of Science ®Google Scholar
• Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221:35-41. doi:10.1016/S0022-1759(98)00170-7. PMID:9894896
   PubMed Web of Science ®Google Scholar